HEALTH SERVICES: Provides relative to psychedelic-assisted therapy. (8/1/26) (EN INCREASE GF EX See Note)

The definition of 'Psychedelic medication' was altered to remove MDMA, limiting the program to ibogaine and psilocybin analogs.

Provisions establishing a 'Psychedelic-Assisted Therapy Initiative' were replaced with a 'Psychedelic-Assisted Therapy Program,' changing the program's name and structure.

Sections regarding clinical trial-enabling studies and drug development clinical trials were deleted, narrowing the bill's focus to direct patient treatment studies only.

Detailed requirements for clinical trial-enabling studies were removed, simplifying the regulatory framework for the program.

Removed redundant instructions regarding document formatting (bold/underline) and page numbering from the body of the text.

Updated the definition of 'Psychedelic medication' to explicitly include MDMA alongside ibogaine, psilocybin, and their analogs.

Rephrased requirements for clinical studies to use consistent language (e.g., changing 'including' to 'all of the following' in lists) to ensure clarity and enforceability.

Added Representatives Adams, Bayham, Berault, Billings, Boyd, Boyer, Brass, Broussard, Bryant, Carpenter, Carver, Chassion, Chenevert, Coates, Cox, Crews, Deshotel, DeWitt, Dickerson, Domangue, Echols, Egan, Fisher, Freeman, Freiberg, Glorioso, Hebert, Chance Henry, Hilferty, Horton, Jackson, Mike Johnson, Kerner, Knox, Lafleur, Jacob Landry, Lyons, Mack, McMakin, Melerine, Miller, Moore, Murray, Riser, Sawyer, Schamerhorn, Spell, St. Blanc, Stagni, Taylor, Ventrella, Walters, Wright, and Wyble to the list of bill sponsors.

The definition of 'psychedelic medication' was broadened to include 'mechanistically-similar analogs' instead of listing only specific drugs like ibogaine and psilocybin.

The program was renamed from 'Program' to 'Initiative,' and the scope was updated to include 'clinical trial-enabling studies' in addition to standard clinical studies.

The bill now explicitly directs the Department of Health to provide information to parishes on how to use opioid settlement funds to support clinical trials and enroll eligible patients.

The criteria for identifying eligible participants were updated to include centers conducting both clinical studies and trial-enabling studies.